Compugen Ltd
CGEN
View Detailed Chart
1.990USD
-0.050-2.45%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
71.52MMarket Cap
5.26P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.45%
5 Days
-4.78%
1 Month
-11.56%
6 Months
+35.37%
Year to Date
+30.07%
1 Year
+30.07%
View Detailed Chart
TradingKey Stock Score of Compugen Ltd
Currency: USD Updated: 2026-03-27Key Insights
Compugen Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 138 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 6.25.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Compugen Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Compugen Ltd Highlights
StrengthsRisks
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 117.47% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 72.76M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 5.39, at a high 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 1.46M shares of this stock.
Analyst Rating
Based on
5
analysts
Strong Buy
Current Rating
6.250
Target Price
+206.37%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Compugen Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Compugen Ltd Info
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Ticker SymbolCGEN
CompanyCompugen Ltd
CEOOphir (Eran)
Websitehttps://cgen.com/
Related Instruments
+0.96%
+1.56%
+0.85%
+2.90%
-1.28%
+1.78%
+1.47%
+0.07%
+0.00%
+2.70%
-2.08%
-0.13%
+0.72%
+2.03%
+2.33%
0.00%
+1.57%
-0.13%
+2.63%
+2.01%Popular Symbols
246.630
-2.170 (-0.87%)
165.170
-2.350 (-1.40%)
67232.000
+610.600 (+0.92%)
251.670
-23.670 (-8.60%)
2035.990
+15.290 (+0.76%)
355.280
-6.550 (-1.81%)
4538.230
+27.450 (+0.61%)
104.021
-0.241 (-0.23%)
1.147
+0.001 (+0.05%)
159.777
+0.118 (+0.07%)
